Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia

Current Opinion in Oncology

Volumn 21, Issue SUPPL. 1, 2009, Pages

  Andersson, Borje S ^a   De Lima, Marcos ^a   Thall, Peter F ^a   Madden, Timothy ^a   Russell, James A ^b   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Alberta Bone Marrow Transplant Program   (Canada)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Cyclophosphamide; Fludarabine; Intravenous busulfan; Myelodysplastic syndrome; Reduced toxicity conditioning therapy

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BAYES THEOREM; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DONOR; DRUG FORMULATION; DRUG SAFETY; EVENT FREE SURVIVAL; FOLLOW UP; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MORTALITY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; TREATMENT DURATION;

ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; BUSULFAN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; RABBITS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 68049107377     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000357469.83960.12     Document Type: Article

References (23)

1. Curtis RE, Rowlings PA, Deeg JH, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336:897-904.
2. Socie G, Curtis RE, Deeg JH, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18:348-357.
3. Baker SK, DeFor TE, Burns LJ, et al. New malignancies after blood and marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21:1352-1358.
4. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:2208-2214.
5. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309:1347-1353.
6. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for acute leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70:1382-1388.
7. Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81:2187-2193.
8. Hartman AR, Williams S, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22:439-443.
9. Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98:3569-3574.
10. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 1996; 37:401-408.
11. Thall PF, Champlin RE, Andersson BS. Comparisson of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 2004; 33:1191-1199.
12. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8:477-485.
13. Hassan M, Ljungman P, Ringden O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25:915-924.
14. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101:2043-2048.
15. Terenzi A, Aristei C, Aversa F, et al. Efficacy of fludarabine as an immuno-supressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc 1996; 28:3101.
16. Ghandi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41:93-103.
17. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8:145-154.
18. De Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104:857-864.
19. Andersson BS, de Lima M, Thall PF, et al. Once daily IV busulfan and fludarabine compares favorably with IV busulfan and cyclophosphamide (IV BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008; 14:672-684.
20. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97:631-637.
21. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118:385-400.
22. Burnett AK. Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults. Cancer Chemother Pharmacol 2001; 48 (Suppl. 1):S53-S58.
23. Geddes M, Kangarloo BS, Naveed F, et al. High busulfan exposure is associated with worse outcomes in daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14:220-228.